Healthcare Industry News: Acute Coronary Syndrome
News Release - February 26, 2008
BSP's New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility StudyBSP's HyperQ(TM) Monitoring System will Allow Bedside Detection of Ischemic Events and Myocardial Infarction (Heart Attack)
TEL AVIV, Israel, February 26 (HSMN NewsFeed) -- BSP (Biological Signal Processing Ltd.) an Israeli company which develops and markets systems for non-invasive diagnosis and monitoring of ischemic heart disease, announces successful results in detecting ischemic events using its proprietary HyperQ technology in resting conditions.
The successful results of the study indicate that the HyperQ(TM) technology, based on sophisticated analysis of high-frequency ECG components, can be implemented in two products: (i) bedside monitoring system for early detection of transient ischemic episodes and (ii) a resting ECG system for sensitive diagnosis of Acute Coronary Syndrome, including myocardial infarction. A highly important clinical application of these two devices is the identification of heart attacks that are not accompanied by changes in standard ECG.
The results of the study showed that both HyperQ(TM) indices detected ischemia more accurately than ST analysis. Overall accuracy of HyperQ-based analysis was found to be 96% for the intensity-based index and 82% for the morphology-based index, both significantly higher than the accuracy of the conventional ST segment analysis at 75%.
"We are proud to present the first results that indicate clearly the HyperQ's strength in ischemia monitoring in a resting condition," said Dr. Amir Beker, Founder & CEO of BSP. "This carries an immense clinical value to cardiac patients, and marks the feasibility of BSP's next product line - the monitoring and resting HyperQ systems, which are planned to be offered to the market by early 2009. BSP will launch the commercial introduction of the HyperQ(TM) Stress System in the US at the 57th ACC Meeting this March." added Dr. Beker.
BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP's HyperQ technology is implemented in cardiac systems that offer highly reliable, low-cost and risk free cardiac monitoring and allows, for the first time, an effective diagnosis of Ischemic Heart Diseases in broad populations. BSP's HyperQ(TM) System for Stress Tests has received FDA clearance and obtained CE marking.
BSP was founded in 2000 by Dr. Amir Beker, and Ariel Landau, had completed a successful IPO in mid-2006 and is traded on the Tel Aviv Stock Exchange.
Source: Biological Signal Processing
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.